Clinical trial
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689
Study timeline
Study start (actual)2026-03-13Date precision: day
Registry last updated2026-09-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
TNX-103DRUG
Sponsors & collaborators
Tenax Therapeutics, Inc.lead sponsor
Mapped research locations
BostonMassachusetts, United States1ChicagoIllinois, United States1St LouisMissouri, United States1DurhamNorth Carolina, United States1MinneapolisMinnesota, United States1OmahaNebraska, United States1RochesterMinnesota, United States1CharlestonSouth Carolina, United States1MadisonWisconsin, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07436689 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.